Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Patient treatment preferences in relapsed/refractory multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 03.12.18
Views: 199
Rating:

Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos

Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos meet in San Diego at the American Society of Hematology 2018 conference for an educational multiple myeloma panel discussion.

Their talk covers patient treatment preferences in relapsed/refractory multiple myeloma, and how this should impact treatment decisions made for this patient population.

Dr Mikhael chairs the discussion, opening the talk by outlining the potential treatment options available for relapsed/refractory multiple myeloma patients, and asking Prof Terpos to describe what ‘patient centred care’ looks like in his clinic.

He then directs the talk to Prof Chim, asking him, with all the different treatment options there are available for multiple myeloma patients, how he matches an individual patient to the therapy they should receive. Chim outlines a number of different factors that come into play when selecting a therapy for a patient and the conversations that should be had with the individual when making these decisions.

Dr Mikhael then summarises the key themes surrounding patient treatment preferences in relapsed/refractory multiple myeloma patients that have been seen from the data presented at ASH 2018; how the results reflect individual preferences, the changing trend in preference that is seen early in the disease course compared to later on, and the particular adverse events that patients look to avoid.

Prof Terpos then adds how the psychology and age of the patient can influence their preferred choice of treatment and discusses the convenience of different therapies for patients, with reference to how often they have to come in to clinic for treatments.

The discussion then moves to neuropathy in multiple myeloma patients and Prof Chim and Dr Mikhael discuss the significance of this adverse event in their patients and the preference surrounding this.
Dr Mikhael then directs the conversation to the evidence of the benefits of enhanced communication with Multiple Myeloma patients, and how this can impact their quality and quantity of life.

The discussion is finalised by summarising the key themes of the conversation and how communication with the patient can influence their long term outcomes.

This programme has been supported by an unrestricted educational grant from Takeda Pharmaceutical Company

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation